NCT02051985

Brief Summary

The purpose of this study is to evaluate the feasibility and the short-term effects of an early-start aerobic exercise training program on functional capacity, symptoms and neurohormonal activation in chronic heart failure patients with recent acute hemodynamic decompensation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2013

Typical duration for not_applicable

Geographic Reach
1 country

9 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2013

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

January 29, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 31, 2014

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2015

Completed
Last Updated

January 31, 2014

Status Verified

January 1, 2014

Enrollment Period

1.7 years

First QC Date

January 29, 2014

Last Update Submit

January 29, 2014

Conditions

Keywords

Chronic heart failureHeart decompensationAerobic exercise trainingFunctional capacityDyspneaBeta-adrenergic receptor signaling

Outcome Measures

Primary Outcomes (1)

  • Distance walked at 6-min walking test

    Change from baseline in distance walked at 6-min walking test

    12 days of intervention

Secondary Outcomes (4)

  • Aerobic exercise training safety and tolerability

    12 days of treatment

  • Patient-reported dyspnea, evaluated by a 7-point Likert scale

    12 days of intervention

  • Levels of lymphocyte G protein-coupled receptor kinase-2

    12 days of intervention

  • Levels of circulating inflammatory and angiogenetic markers (TNF-alfa, Interleukin-6, Angiopoietin 2 and VEGF)

    12 days of intervention

Study Arms (2)

Aerobic exercise training

EXPERIMENTAL
Other: Aerobic exercise training

Standard physical therapy

ACTIVE COMPARATOR
Other: Standard physical therapy

Interventions

Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration). Days 3-4: as days 1-2 + unloaded bedside cycle ergometer (3 sessions/day, each 5-6 minutes duration). Days 5-6: as days 1-2 + bedside cycle ergometer at 10 W (3 sessions/day, each 15-20 minutes duration). Days 7-12: as days 1-2 + bedside cycle ergometer at 10-20 W (3 sessions/day, each 15-20 minutes duration). In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day.

Aerobic exercise training

Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration). Days 3-12: active assisted mobilization (1 session/day, 30 minutes duration). In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day.

Standard physical therapy

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • history of chronic heart failure for at least 6 months, with ongoing acute decompensation defined as onset or worsening of heart failure signs and/or symptoms during the previous 15 days with need of intravenous diuretic and/or vasodilator therapy;
  • age \>18 years
  • left ventricular ejection fraction \<40%
  • proBNP \>1000 pg/ml at admission

You may not qualify if:

  • ongoing cardiogenic shock
  • need of intravenous inotropic therapy
  • acute coronary syndrome during the preceding 3 months
  • clinical and/or instrumental evidence of myocardial ischemia and/or life-threatening arrhythmias
  • previous cardiac valve surgery
  • creatinine \>2.5 mg/dl at admission
  • severe comorbidities limiting functional capacity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Fondazione Salvatore Maugeri, IRCCS - Scientific Institute of Cassano Murge

Cassano Murge, 70020, Italy

RECRUITING

Fondazione Salvatore Maugeri, IRCCS - Scientific Institute of Lumezzane

Lumezzane, 25066, Italy

RECRUITING

Fondazione Salvatore Maugeri - Scientific Institute of Milano

Milan, 20138, Italy

RECRUITING

Fondazione Salvatore Maugeri, IRCCS - Scientific Institute of Montescano

Montescano, 27040, Italy

RECRUITING

Fondazione Salvatore Maugeri, IRCCS - Scientific Institute of Pavia

Pavia, 27100, Italy

RECRUITING

Fondazione Salvatore Maugeri, IRCCS - Scientific Institute of Telese Terme

Telese Terme, 82037, Italy

RECRUITING

Fondazione Salvatore Maugeri - Presidio Major of Torino

Torino, 10124, Italy

RECRUITING

Fondazione Salvatore Maugeri, IRCCS - Scientific Institute of Tradate

Tradate, 21049, Italy

RECRUITING

Fondazione Salvatore Maugeri, IRCCS - Scientific Institute of Veruno

Veruno, 28010, Italy

RECRUITING

Related Links

MeSH Terms

Conditions

Heart FailureDyspnea

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesRespiration DisordersRespiratory Tract DiseasesSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Pantaleo Giannuzzi, MD

    Fondazione Salvatore Maugeri - Scientific Institute of Veruno

    STUDY CHAIR
  • Alessandro Mezzani, MD

    Fondazione Salvatore Maugeri - Scientific Institute of Veruno

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Alessandro Mezzani, MD

CONTACT

Pantaleo Giannuzzi, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

January 29, 2014

First Posted

January 31, 2014

Study Start

October 1, 2013

Primary Completion

June 1, 2015

Study Completion

September 1, 2015

Last Updated

January 31, 2014

Record last verified: 2014-01

Locations